Oncoinvent Hits 50% Enrollment in Phase 2 Radspherin Trial for Ovarian Cancer

5 days ago

An update from Oncoinvent ASA ( ($BRRGF) ) is now available. Oncoinvent has reached the halfway point in patient recruitment for its Phase 2 trial ...

Read Entire Article

Oncoinvent Hits 50% Enrollment in Phase 2 Radspherin Trial for Ovarian Cancer

Related

CFTC sues Kentucky after state’s prediction market lawsuits

Bitcoin, Ethereum, XRP, Dogecoin Drop Further Amid Global Ch...

Dollar at 13-month high as rate hike bets, stock rout boost ...

MSCI Maintains Korea's Emerging Market Status in Latest Revi...

Asian Currencies Consolidate; May be Weighed by Risk-Off Sen...

Tokenized Nasdaq fund plans Dubai launch

NVIDIA, AWS Launch AI Infrastructure for Production Scale

How the housing bill quietly helps out fintech, crypto

Popular

SPACEX HELD STRONG ‼️ 7 DAYS LEFT 🚨 SPCX PRICE PREDICTION

Japan Is Running Out of Options on Yen, TD’s Bharadwaj Says

Billionaire investor Philippe Laffont on why he owns semi ca...

CZ Says Hyperliquid Found A No-KYC Niche Binance Cannot Touc...

Binance Pool Supports Retail Miners Amid Market Compression

Trump Post-Quantum Crypto Order Puts Blockchain Security Deb...